TY - JOUR
T1 - Comparing hypertrophy of the future liver remnant for two different strategies of portal vein embolization in patients with bilobar colorectal liver metastases – a retrospective European multicentre study
AU - Björk, Dennis
AU - Reese, Tim
AU - Holmen Longva, Anne M.
AU - Kiim, Kristian S.
AU - Evers, Maximilian
AU - Larsen, Peter N.
AU - Aagaard Schultz, Nicolai
AU - Røsok, Bård I.
AU - Carling, Ulrik
AU - Holmquist, Fredrik
AU - Lindell, Gert
AU - Sandström, Per
AU - Böcker, Jörg
AU - Gilg, Stefan
AU - Engstrand, Jennie
AU - Sturesson, Christian
AU - Oldhafer, Karl J.
AU - Sparrelid, Ernesto
AU - Björnsson, Bergthor
N1 - Publisher Copyright:
© 2025 The Author(s)
PY - 2025/12/3
Y1 - 2025/12/3
N2 - Background: Portal vein embolization (PVE) is a well-established technique for inducing liver hypertrophy in the future liver remnant (FLR) before major hepatectomy. A frequently used method in bilobar disease is the two-stage hepatectomy (TSH) technique combined with PVE (TSH-PVE). A novel approach is PVE, followed by a one-stage hepatectomy (OSH), combining major hepatectomy with clearing of the FLR (PVE-OSH). This study aimed to compare FLR hypertrophy between these two strategies for induced liver hypertrophy. Material/methods: Patients with bilobar colorectal liver metastases (CRLM) who underwent PVE from January 2013 to December 2021 were included in this retrospective, multicenter study. Aspects of hypertrophy of the FLR were compared between the groups. Results: The study included 188 patients, 127 in the PVE-OSH group and 61 in the TSH-PVE group. There were no statistically significant differences between the two groups regarding FLR hypertrophy measured by absolute and relative growth, degree of hypertrophy or kinetic growth rate. No major complications were reported. Discussion/conclusion: No differences in FLR hypertrophy were demonstrated between the two different treatment strategies of TSH-PVE or PVE-OSH. This supports PVE-OSH as a feasible treatment option that reduces the surgical burden for patients with advanced, bilobar CRLM disease.
AB - Background: Portal vein embolization (PVE) is a well-established technique for inducing liver hypertrophy in the future liver remnant (FLR) before major hepatectomy. A frequently used method in bilobar disease is the two-stage hepatectomy (TSH) technique combined with PVE (TSH-PVE). A novel approach is PVE, followed by a one-stage hepatectomy (OSH), combining major hepatectomy with clearing of the FLR (PVE-OSH). This study aimed to compare FLR hypertrophy between these two strategies for induced liver hypertrophy. Material/methods: Patients with bilobar colorectal liver metastases (CRLM) who underwent PVE from January 2013 to December 2021 were included in this retrospective, multicenter study. Aspects of hypertrophy of the FLR were compared between the groups. Results: The study included 188 patients, 127 in the PVE-OSH group and 61 in the TSH-PVE group. There were no statistically significant differences between the two groups regarding FLR hypertrophy measured by absolute and relative growth, degree of hypertrophy or kinetic growth rate. No major complications were reported. Discussion/conclusion: No differences in FLR hypertrophy were demonstrated between the two different treatment strategies of TSH-PVE or PVE-OSH. This supports PVE-OSH as a feasible treatment option that reduces the surgical burden for patients with advanced, bilobar CRLM disease.
UR - http://www.scopus.com/inward/record.url?scp=105025530636&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2025.12.006
DO - 10.1016/j.hpb.2025.12.006
M3 - Journal article
C2 - 41419351
AN - SCOPUS:105025530636
SN - 1365-182X
JO - HPB
JF - HPB
ER -